Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Phase 4

Recruiting

• Conditions: Hypomagnesemia
• Interventions: Drug: Magnesium Citrate 100 MG

• Registration Number: NCT03088852
• Lead Sponsor: Frieda Wolf

Brief Summary

Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-10-27
• Study First Submitted QC: 2017-03-19
• Study First Posted: 2017-03-23
• Study Start: 2017-05-10
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-16
• Last Update Posted: 2025-03-18
• Primary Completion: 2025-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

• Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.

Exclusion Criteria

• A patient unable to give consent.
• A patient admitted for an elective procedure.
• A patient in critical condition or dying.
• Patients with advanced kidney disease with eGFR<15ml/min or on dialysis.
• Patients with severe diarrhea, precluding use of magnesium citrate.
• Patients already receiving magnesium supplements.
• Patients with severe malnutrition or life-threatening hypomagnesemia (serum level <1mg/dL), requiring intravenous and oral replacement of magnesium.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental group	Magnesium Citrate 100 MG	After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.

Primary Outcome Measures

Name	Time	Method
compare mortality	one year	To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement.

Secondary Outcome Measures

Name	Time	Method
Hospitalization	one year	Length in days of hospitalization.

Trial Locations

Locations (1)

Emek Medical Center; 🇮🇱 Afula, Israel